But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study. And through the first nine months of 2025, Zepbound generated $9.3 billion ...

Bengaluru: Strides Pharma Science has announced that the U.S. Food and Drug Administration (USFDA) has concluded inspection ...

Strides Pharma Science Ltd's Chestnut Ridge facility received four procedural FDA observations, with no impact on supply.

Get the latest Granules India share price today on NSE & BSE. Explore Granules India stock analysis, financial performance, market capitalization, dividend history, and future outlook for investors in ...

The subcutaneous formulation of the bispecific antibody reduces treatment time to 1 minute vs 2-4 hours with IV infusion.

Liquid Drop Formula Features Grape Seed Extract, Green Tea, GABA and Antioxidant Botanicals Targeting Inner Ear Health and ...

The FDA has granted approval to a subcutaneous formulation of mosunetuzumab (Lunsumio VELO; Genentech/Roche) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma ...

Shield Therapeutics, which has a base in Gateshead, has secured an extension for its iron deficiency drug, meaning it can now ...

The market for weight-loss drug is expected to expand to more than $150 billion in revenue by the early 2030s, thanks to the ...

The U. S. Food and Drug Administration has approved an oral formulation of semaglutide for a new drug or biologic under the Prescription Drug User Fee Act. According to a news release, clinical trials ...

Novo Nordisk's ADRs rose 8% higher to $51.99 in post-market trading on volume that topped 1.2 million ADRs. The stock ended the day's market session little changed at $48.10. The approval makes Wegovy ...

Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.